ArticleIn vivo (Athens, Greece)
Deep Immunophenotyping Reveals a Resilient Tph-ABC Axis in Difficult-to-treat Rheumatoid Arthritis: A Case Report of JAK Inhibitor Failure Complicated by Herpes Zoster and Thrombosis.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe management of difficult-to-treat rheumatoid arthritis (D2T-RA) is frequently complicated by the occurrence of severe adverse events (SAEs) that severely restrict therapeutic options. Emerging evidence suggests that refractory disease in seropositive patients may be driven by resilient immune cell subsets, such as T peripheral helper (Tph) cells and age-associated B cells (ABCs), which escape standard immune suppression. CASE REPORT: We present the case of a 33-year-old female with high-titer seropositive RA [Anti-cyclic citrullinated peptide (CCP) >200 U/ml] and Sjogren's syndrome who exhibited sequential resistance to conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and tumor necrosis factor (TNF) inhibitors. Subsequent treatment with the janus kinase (JAK) inhibitor upadacitinib was complicated by multi-dermatomal Herpes Zoster infection and a deep vein thrombosis (DVT) event, necessitating permanent drug withdrawal due to safety concerns. Despite a mechanistic switch to B-cell depletion therapy (rituximab), the patient maintained high disease activity (DAS28: 4.98). Longitudinal deep immunophenotyping revealed a distinct pathogenic cellular signature characterizing this refractory state. We observed a sustained expansion of programmed death-1 -positive (PD-1
conclusionThis case highlights the clinical complexity of managing D2T-RA when JAK inhibitors are contraindicated due to thromboembolic and infectious risks. The immunophenotypic data suggests that a resilient Tph-ABC interaction axis underpins the mechanism of therapeutic resistance, pointing towards the need for combination strategies targeting these specific cellular reservoirs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.